{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Garcia-Arriaza J"],"funding":["Ferrovial","Fundación Mapfre","MEC | Instituto de Salud Carlos III","MEC | Consejo Superior de Investigaciones Científicas","Fondo Supera COVID-19","Fundación Banco Santander"],"pagination":["JVI.02260-20"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8092708"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["95(7)"],"pubmed_abstract":["Vaccines against SARS-CoV-2, the causative agent of the COVID-19 pandemic, are urgently needed. We developed two COVID-19 vaccines based on modified vaccinia virus Ankara (MVA) vectors expressing the entire SARS-CoV-2 spike (S) protein (MVA-CoV2-S); their immunogenicity was evaluated in mice using DNA/MVA or MVA/MVA prime/boost immunizations. Both vaccines induced robust, broad and polyfunctional S-specific CD4+ (mainly Th1) and CD8+ T-cell responses, with a T effector memory phenotype. DNA/MVA immunizations elicited higher T-cell responses. All vaccine regimens triggered high titers of IgG antibodies specific for the S, as well as for the receptor-binding domain; the predominance of the IgG2c isotype was indicative of Th1 immunity. Notably, serum samples from vaccinated mice neutralized S"],"journal":["Journal of virology"],"pubmed_title":["COVID-19 vaccine candidates based on modified vaccinia virus Ankara expressing the SARS-CoV-2 spike induce robust T- and B-cell immune responses and full efficacy in mice."],"pmcid":["PMC8092708"],"funding_grant_id":["COV20/00151","2020E84"],"pubmed_authors":["Perez P","Sorzano COS","Esteban M","Casasnovas JM","Lazaro-Frias A","Sancho D","Gastaminza P","Zamora C","Garcia-Arriaza J","Del Fresno C","Garaigorta U"],"additional_accession":[]},"is_claimable":false,"name":"COVID-19 vaccine candidates based on modified vaccinia virus Ankara expressing the SARS-CoV-2 spike induce robust T- and B-cell immune responses and full efficacy in mice.","description":"Vaccines against SARS-CoV-2, the causative agent of the COVID-19 pandemic, are urgently needed. We developed two COVID-19 vaccines based on modified vaccinia virus Ankara (MVA) vectors expressing the entire SARS-CoV-2 spike (S) protein (MVA-CoV2-S); their immunogenicity was evaluated in mice using DNA/MVA or MVA/MVA prime/boost immunizations. Both vaccines induced robust, broad and polyfunctional S-specific CD4+ (mainly Th1) and CD8+ T-cell responses, with a T effector memory phenotype. DNA/MVA immunizations elicited higher T-cell responses. All vaccine regimens triggered high titers of IgG antibodies specific for the S, as well as for the receptor-binding domain; the predominance of the IgG2c isotype was indicative of Th1 immunity. Notably, serum samples from vaccinated mice neutralized S","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Mar","modification":"2025-06-01T01:37:01.305Z","creation":"2022-02-10T09:53:52.54Z"},"accession":"S-EPMC8092708","cross_references":{"pubmed":["33414159"],"doi":["10.1128/JVI.02260-20"]}}